Redwood City, California-based Proteus Digital Health announced its first US healthcare provider customer, Barton Health, which will prescribe the company’s Proteus Discover to patients. The company says this is the first time its technology has been implemented outside of a clinical trial setting in the US. Barton Health, a health system in Lake Tahoe, California, will use the medication adherence platform, which includes Proteus’s FDA-cleared ingestible sensor, in populations with uncontrolled and co-morbid hypertension. Implementation for other chronic conditions will follow if the first use case goes well.
“Patients struggle with medication adherence for various reasons. When a non-adherent patient is not seeing results and the physician believes a patient is taking a medication, this may lead to unnecessary changes in treatment which can be costly for the patient and the health system,” Dr. Purvance, CEO of Barton Health, said in a statement. “This new product offering provides a data-driven communication channel between the medical provider and the patient that empowers the patient to take the appropriate dose of medication and better understand the importance of daily activity levels and other lifestyle changes.” FULL REPORT
